Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study |
| |
| Authors: | Alastair J. Flint Anthony J. Rothschild Ellen M. Whyte George S. Alexopoulos Benoit H. Mulsant Patricia Marino Samprit Banerjee Cristina D. Pollari Yiyuan Wu Aristotle N. Voineskos Barnett S. Meyers |
| |
| Affiliation: | 1. Department of Psychiatry (AJF, BHM, ANV), University of Toronto, ON, Canada;2. Centre for Mental Health, University Health Network (AJF), Toronto, ON, Canada;3. University of Massachusetts Medical School and UMass Memorial Health Care (AJR), Worcester, MA;4. Department of Psychiatry (EMW), UPMC Western Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA;5. Department of Psychiatry (GSA, PM, CDP, BSM)), Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital, Westchester Division, NY;6. Centre for Addiction and Mental Health (BHM, ANV), Toronto, ON, Canada;7. Department of Healthcare Policy and Research (SB, YW), Weill Cornell Medical College, New York, NY |
| |
| Abstract: | ObjectiveTo examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.MethodsTwo hundred and sixty-nine men and women aged 18–85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures.ResultsParticipants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18–59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures.ConclusionOlder patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
